	US 12,269,863 B2
	Bispecific T cell engager and uses thereof
Hsin-Yi Huang, Taipei (TW); Cheng Hao Liao, Taipei (TW); and Chun-Ming Lin, Taipey (TW)
Assigned to MANYSMART THERAPEUTICS, INC., Tapei (TW)
Appl. No. 17/057,957
Filed by MANYSMART THERAPEUTICS, INC., Tapei (TW)
PCT Filed May 23, 2019, PCT No. PCT/US2019/033752 § 371(c)(1), (2) Date Nov. 23, 2020, PCT Pub. No. WO2019/226894, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/675,208, filed on May 23, 2018.
Prior Publication US 2021/0261645 A1, Aug. 26, 2021
Int. Cl. A61K 39/00 (2006.01); A61P 31/22 (2006.01); A61P 35/00 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/70535 (2013.01) [A61P 31/22 (2018.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2319/02 (2013.01)]

14 Claims

1. An isolated fusion protein comprising:

(a) an Fc-binding extracellular domain of human CD16A, wherein the Fc-binding extracellular domain of human CD16A has the amino acid sequence as set forth in SEQ ID NO: 2; and

(b) an anti-human CD3 single-chain variable fragment that both specifically binds to human CD3 and activates human T cells;

and wherein the C-terminal residue of SEQ ID NO: 2 is directly fused to the N-terminal residue of the anti-human CD3 single-chain variable fragment, wherein the anti-human CD3 single-chain variable fragment has the amino acid sequence as set forth in SEQ ID NO: 4.